Oral cancer (Oral Squamous Cell Carcinoma) is the sixth most common cancer in the world. There will be over 650,000 newly diagnosed oral cancer cases worldwide in 2016 and over 50,000 newly diagnosed cases in the United States alone.

In the spectrum of cancer survivability, oral cancer falls towards the more dangerous end. While early detection causes survivability and non-radical treatment to skyrocket to over 90%, most patients (70%) unfortunately are diagnosed at late stages 3 or 4.  Treatment at those later stages is often terribly disfiguring. It involves radical surgery (removing the patient’s mandible and often some of the tongue) followed by chemotherapy and radiation therapy. That course of treatment also makes it one of the more expensive cancers to treat. Further, about 65% of those with late-stage diagnosis never return to work.

A new salivary-based genetic testdeveloped in a collaborative effort between NIH, UCLA, world-renowned scientist Dr. David Wong and a small company named PeriRx will completely change the dynamic of oral cancer detection — which up until now has primarily been performed by dentists usingunreliable visual techniques. With salivary diagnostics, the early-detection process can now be greatly enhanced with a simple laboratory test of a saliva sample based on genetic markers developed to identify oral cancer. 

This will dramatically increase the likelihood not only of survival but also of survival without terribly disfiguring surgery. Salivary-based diagnostics, as contrasted with blood-based testing, has yet to be highlighted in the media — even though its impact on oral cancer detection is quite remarkable.

Ask your dental health professional about this test or follow this link… PeriRX.com